Michael Levy, MD’s Post

So excited to be at ESMO 2025 here in Berlin! Gilead and Kite are working hard to create the future of oncology. This year at ESMO, we are focused on Triple Negative Breast Cancer (TNBC), the most aggressive form of breast cancer, working to bring new hope to patients. Making bold strides against cancer requires a strategy built on the power of partnerships, and groundbreaking technologies. We are purposefully building our pipeline to address the greatest unmet needs. From antibody-drug conjugates and small molecules to cell therapy-based approaches, our research and development programs are creating possibilities for people with underserved and difficult-to-treat cancers.